Full history for every metric is available with a Kvantra account
Eusol Biotech Co.,Ltd. (6652.TWO)
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | TWD m | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Operating profit | TWD m | -47 | -47 | |||||
| Net profit | TWD m | -114 | -123 | -18 | -52 | -31 | -40 | -40 |
| EPS reported | TWD | -0.29 | -0.30 | |||||
| Operating cashflow per share | TWD | -0.24 | -0.24 | |||||
| Capex per share | TWD | 0.02 | 0.02 | |||||
| FCF per share | TWD | -0.25 | -0.25 | |||||
| Free cash flow | TWD m | -35 | -35 | |||||
| Net debt | TWD m | -299 | -290 | |||||
| Book value equity | TWD m | 330 | 330 | |||||
| Book value per share | TWD | 2.41 | 2.41 | |||||
| Number of shares | m | 137 | 137 | |||||
| DPS (TTM paid) | TWD | 0.00 | 0.00 |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.45 | 0.81 | |||||
| P/S LTM | x | 389.83 | 129.28 | |||||
| P/FCF LTM | x | -23.36 | -7.75 | |||||
| EV/EBITDA LTM | x | -14.42 | 0.50 | |||||
| EV/Sales LTM | x | 303.05 | -10.13 | |||||
| Earnings Yield LTM | % | -4.99% | -15.05% | |||||
| FCF Yield | % | -4.28% | -12.91% | |||||
| Quality | ||||||||
| ROE | % | -12.25% | -11.93% | |||||
| ROIC | % | -13.80% | -13.80% | |||||
| Operating margin | % | -2267.5% | -2267.5% | |||||
| Gross margin | % | -133.03% | -133.03% | |||||
| FCF/Sales | % | -1668.8% | -1668.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.08 | -3.08 | |||||
| Net Debt/EBITDA | x | 4.13 | 4.31 | |||||
| EBIT/Net interest | x | -359.50 | -359.50 | |||||
| Net debt/market cap | % | -36.87% | -107.83% | |||||
| Net debt/Equity | x | -0.90 | -0.88 | |||||
| Gross debt/equity | x | 0.03 | 0.03 | |||||
Company overview
Eusol Biotech Co.,Ltd. is a biopharmaceutical firm primarily dedicated to the discovery and advancement of innovative biotechnological treatments for various sleep-related conditions. Its current development portfolio showcases two key candidates: ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) designed to restore and repair neuronal function; and SM-1, a singular capsule formulation that combines three commercially available sedative medications. The company commenced operations in 1994 and maintains its principal offices in Taipei, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Eusol Biotech Co.,Ltd. (6652.TWO)
Eusol Biotech Co.,Ltd. is a biopharmaceutical firm primarily dedicated to the discovery and advancement of innovative biotechnological treatments for various sleep-related conditions. Its current development portfolio showcases two key candidates: ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) designed to restore and repair neuronal function; and SM-1, a singular capsule formulation that combines three commercially available sedative medications. The company commenced operations in 1994 and maintains its principal offices in Taipei, Taiwan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free